- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02137720
Translating Telephonic Diabetes Self-management Support to Primary Care Practice
July 24, 2020 updated by: Jeffrey Gonzalez, Albert Einstein College of Medicine
Translating Telephonic Diabetes Self-management Support to Primary Care Practice: The NYC Care Calls Trial
The goal of this study is to evaluate the implementation and effectiveness of an intervention to improve diabetes self-management, emotional distress and metabolic control among adults with type 2 diabetes receiving care in primary care practices throughout New York City.
The program will be implemented by the New York City Department of Health, through their Primary Care Improvement Project.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
812
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 11101
- New York City Department of Health and Mental Hygiene
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 21 years of age and older
- Receiving treatment for diabetes at selected primary care practices throughout New York City
- Most recent HbA1c ≥ 7.5% (max 3 months prior to randomization)
- Ability to speak and read English or Spanish (or someone in the household who will read to them)
- Access to a telephone
- Willing to give informed consent to participate and accept random assignment.
Exclusion Criteria:
- Stated intention to move out of the New York City area during the next year
- Mental incapacity (e.g., confusion) evident on first telephone contact by Department of Health staff
- Treatment provider deems that the patient is inappropriate for the trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Telephonic Diabetes Self-Management Support
This group receives all the Educational Print Materials received by the comparison condition plus telephone calls from a health educator to provide tailored diabetes self-management training and support.
Participants with significant emotional distress at baseline also receive additional calls focused on distress management.
|
|
Active Comparator: Educational Print Materials
Participants randomized to this arm will receive print materials on diabetes, glycemic control, self-management, and distress/depression.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c
Time Frame: Change from baseline at 12 months
|
Obtained from electronic medical record.
|
Change from baseline at 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diabetes Self-Management
Time Frame: Change from baseline at 12 months
|
Measured by self-report questionnaire
|
Change from baseline at 12 months
|
Medication Adherence
Time Frame: Change from baseline at 12 months
|
Measured by self-report questionnaire
|
Change from baseline at 12 months
|
Diabetes-related distress
Time Frame: Change from baseline at 12 months
|
Measured by self-report questionnaire
|
Change from baseline at 12 months
|
Depressive symptoms
Time Frame: Change from baseline at 12 months
|
Measured by self-report questionnaire
|
Change from baseline at 12 months
|
Blood pressure
Time Frame: Baseline and 12 months
|
Obtained from electronic medical record.
|
Baseline and 12 months
|
Cholesterol
Time Frame: Baseline and 12 months
|
Obtained from electronic medical record.
|
Baseline and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jeffrey S Gonzalez, PhD, Albert Einstein College Of Medicine
- Principal Investigator: Winfred Y Wu, MD, MPH, New York City Department of Health and Mental Hygiene
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2014
Primary Completion (Actual)
September 20, 2019
Study Completion (Actual)
September 20, 2019
Study Registration Dates
First Submitted
May 8, 2014
First Submitted That Met QC Criteria
May 9, 2014
First Posted (Estimate)
May 14, 2014
Study Record Updates
Last Update Posted (Actual)
July 27, 2020
Last Update Submitted That Met QC Criteria
July 24, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-422
- 1R18DK098742-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Telephonic Diabetes Self-Management Support
-
University of MichiganRecruiting
-
University of ArkansasPatient-Centered Outcomes Research InstituteActive, not recruitingDiabetes Mellitus, Type 2United States
-
American Association of Diabetes EducatorsBristol-Myers SquibbUnknownDiabetes Mellitus Type 2United States
-
University of MichiganNational Institutes of Health (NIH); National Institute on Aging (NIA); Blue...Completed
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of ArkansasNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Universidad de AntioquiaCompletedDiabetes Mellitus, Type 2Colombia
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of CincinnatiNot yet recruitingDiabetes Mellitus, Type 2 | PreDiabetesUnited States
-
University of ArkansasNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingType 2 DiabetesUnited States